In Vitro Time-Kill of Common Ocular Pathogens with Besifloxacin Alone and in Combination with Benzalkonium Chloride

por Blondeau, Joseph, DeCory, Heleen
Publicado 2021

Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate

por Comstock, Timothy L., DeCory, Heleen H.
Publicado 2012

The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies

por Cavet, Megan E., DeCory, Heleen H.
Publicado 2018

Antibiotic resistance among bacterial conjunctival pathogens collected in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study

por Asbell, Penny A., DeCory, Heleen H.
Publicado 2018

In Vitro Inhibition of Evaporation with Perfluorohexyloctane, an Eye Drop for Dry Eye Disease

por Vittitow, Jason, Kissling, Robert, DeCory, Heleen, Borchman, Douglas
Publicado 2023

Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop

por Coffey, Martin J, DeCory, Heleen H, Lane, Stephen S
Publicado 2013

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates

por Sanfilippo, Christine M., Allaire, Catherine M., DeCory, Heleen H.
Publicado 2017

Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies

por Fong, Raymond, Cavet, Megan E, DeCory, Heleen H, Vittitow, Jason L
Publicado 2019

Antibiotic Resistance Among Pediatric-Sourced Ocular Pathogens: 8-Year Findings From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study

por Alter, Sherman J., Sanfilippo, Christine M., Asbell, Penny A., DeCory, Heleen H.
Publicado 2019

Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018

por Asbell, Penny A., Sanfilippo, Christine M., Sahm, Daniel F., DeCory, Heleen H.
Publicado 2020

Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin o...

por DeCory, Heleen H., Sanfilippo, Christine M., Proskin, Howard M., Blondeau, Joseph M.
Publicado 2020

Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophtha...

por Blondeau, Joseph M, Proskin, Howard M, Sanfilippo, Christine M, DeCory, Heleen H
Publicado 2021

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility prof...

por Haas, Wolfgang, Gearinger, Lynne S, Usner, Dale W, DeCory, Heleen H, Morris, Timothy W
Publicado 2011

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections

por Silverstein, Bruce E, Morris, Timothy W, Gearinger, Lynne S, DeCory, Heleen H, Comstock, Timothy L
Publicado 2012

Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: Preliminary indications from a secondary analysis of the COMACS s...

por Sonuga-Barke, Edmund JS, Swanson, James M, Coghill, David, DeCory, Heleen H, Hatch, Simon J
Publicado 2004

An Evaluation of Staphylococci from Ocular Surface Infections Treated Empirically with Topical Besifloxacin: Antibiotic Resistance, Molecular Characteristics, and Clinical Outcomes

por Schechter, Barry A., Sheppard, John D., Sanfilippo, Christine M., DeCory, Heleen H., Asbell, Penny A.
Publicado 2019

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes

por Morris, Timothy W, Gearinger, Lynne S, Usner, Dale W, Paterno, Michael R, DeCory, Heleen H, Comstock, Timothy L, Haas, Wolfgang
Publicado 2011

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery

por Bucci, Frank A, Evans, Ruth E, Amico, Loretta M, Morris, Timothy W, Fluet, Angel T, Sanfilippo, Christine M, DeCory, Heleen H, Comstock, Timothy L
Publicado 2015